340 related articles for article (PubMed ID: 32004105)
1. Treatment options for glucocorticoid-induced osteoporosis.
Chiodini I; Merlotti D; Falchetti A; Gennari L
Expert Opin Pharmacother; 2020 Apr; 21(6):721-732. PubMed ID: 32004105
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoid induced osteoporosis.
Hu K; Adachi JD
Expert Rev Endocrinol Metab; 2019 Jul; 14(4):259-266. PubMed ID: 31094232
[TBL] [Abstract][Full Text] [Related]
3. Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis.
Chiodini I; Falchetti A; Merlotti D; Eller Vainicher C; Gennari L
Expert Rev Endocrinol Metab; 2020 Jul; 15(4):283-298. PubMed ID: 32584619
[TBL] [Abstract][Full Text] [Related]
4. [Glucocorticoid-induced osteoporosis : treatment update].
Soen S
Clin Calcium; 2012 Feb; 22(2):229-35. PubMed ID: 22298077
[TBL] [Abstract][Full Text] [Related]
5. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
Hayakawa N; Suzuki A
Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
[TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
Bultink IE; Baden M; Lems WF
Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
[TBL] [Abstract][Full Text] [Related]
8. High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first.
Lespessailles E; Chapurlat R
Osteoporos Int; 2020 Oct; 31(10):1829-1834. PubMed ID: 32780152
[TBL] [Abstract][Full Text] [Related]
9. Management of glucocorticoid-induced osteoporosis.
Rizzoli R; Adachi JD; Cooper C; Dere W; Devogelaer JP; Diez-Perez A; Kanis JA; Laslop A; Mitlak B; Papapoulos S; Ralston S; Reiter S; Werhya G; Reginster JY
Calcif Tissue Int; 2012 Oct; 91(4):225-43. PubMed ID: 22878667
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates and glucocorticoid-induced osteoporosis: cons.
Lems WF; Saag K
Endocrine; 2015 Aug; 49(3):628-34. PubMed ID: 26041376
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.
Dong B; Zhou Y; Wang J; Li C; Fu Z; Huang Y; Wang Y; Xu L
Horm Metab Res; 2023 Apr; 55(4):236-244. PubMed ID: 36652960
[TBL] [Abstract][Full Text] [Related]
12. Denosumab is effective toward glucocorticoid-induced osteoporosis patients complicated with rheumatic diseases regardless of prior anti-osteoporotic drugs.
Iwamoto N; Okamoto M; Tsuji S; Endo Y; Takatani A; Shimizu T; Umeda M; Fukui S; Sumiyoshi R; Igawa T; Koga T; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Ueki Y; Kawakami A
J Bone Miner Metab; 2019 May; 37(3):554-562. PubMed ID: 30187273
[TBL] [Abstract][Full Text] [Related]
13. When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis.
Hayes KN; Baschant U; Hauser B; Burden AM; Winter EM
Front Endocrinol (Lausanne); 2021; 12():782118. PubMed ID: 34975756
[TBL] [Abstract][Full Text] [Related]
14. New therapeutic targets for osteoporosis.
Anagnostis P; Gkekas NK; Potoupnis M; Kenanidis E; Tsiridis E; Goulis DG
Maturitas; 2019 Feb; 120():1-6. PubMed ID: 30583758
[TBL] [Abstract][Full Text] [Related]
15. [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis].
Kaneko K; Kawai S
Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(3):138-48. PubMed ID: 21720102
[TBL] [Abstract][Full Text] [Related]
16. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis].
Tanaka I
Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010
[TBL] [Abstract][Full Text] [Related]
17. Advances in treatment of glucocorticoid-induced osteoporosis.
Hsu E; Nanes M
Curr Opin Endocrinol Diabetes Obes; 2017 Dec; 24(6):411-417. PubMed ID: 28857847
[TBL] [Abstract][Full Text] [Related]
18. Update on Glucocorticoid Induced Osteoporosis.
Cho SK; Sung YK
Endocrinol Metab (Seoul); 2021 Jun; 36(3):536-543. PubMed ID: 34107602
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-induced osteoporosis: management update.
Adler RA
Curr Osteoporos Rep; 2010 Mar; 8(1):10-4. PubMed ID: 20425085
[TBL] [Abstract][Full Text] [Related]
20. Four-Year Teriparatide Followed by Denosumab
Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
